<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997135</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6455</org_study_id>
    <nct_id>NCT04997135</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Therapeutic Meibomian Gland Expression</brief_title>
  <official_title>Clinical Evaluation of Therapeutic Meibomian Gland Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single centre pilot study to evaluate appearance of the Meibomian glands.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2021</start_date>
  <completion_date type="Anticipated">November 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Meibomian Gland Appearance</measure>
    <time_frame>up to 2-week follow-up</time_frame>
    <description>Meibomian gland appearance will be evaluated on both eyes using a custom image analysis algorithm, which calculates length ratio, width, area, intensity, tortuosity, and contrast</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Visual Acuity</condition>
  <condition>Meibomian Gland</condition>
  <arm_group>
    <arm_group_label>Meibography Subjects</arm_group_label>
    <description>Eligible subjects will undergo testing to evaluate the Meibomian gland appearance</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited and enrolled based on Inclusion/Exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects who meet any of the following criteria will be excluded from&#xD;
             participating in the study:&#xD;
&#xD;
               1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully&#xD;
                  executed copy of the form.&#xD;
&#xD;
               2. Appear able and willing to adhere to the instructions set forth in this clinical&#xD;
                  protocol.&#xD;
&#xD;
               3. Be between 18 and 60 (inclusive) years of age at the time of screening. Inclusion&#xD;
                  Criteria at Baseline Evaluation.&#xD;
&#xD;
               4. The subject must have visual acuity of 0.2 high contrast logMAR or better in&#xD;
                  their current correction or unaided in each eye.&#xD;
&#xD;
               5. The subject must have at least 10 Meibomian glands yielding liquid secretion&#xD;
                  (MGYLS) in central lower eyelid region in each eye.&#xD;
&#xD;
               6. The subject eyelids must be easy to evert, at the Investigator's discretion.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects who meet any of the following criteria will be excluded from&#xD;
             participating in the study:&#xD;
&#xD;
               1. Be currently pregnant or breastfeeding.&#xD;
&#xD;
               2. By self-report, have any ocular or systemic disease, allergies, infection, or use&#xD;
                  of medication that might contraindicate or interfere with contact lens wear, or&#xD;
                  otherwise compromise study endpoints, including infectious disease (e.g.,&#xD;
                  hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human&#xD;
                  Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis,&#xD;
                  Sj√∂gren's syndrome), or history of serious mental illness or seizures. See&#xD;
                  Section 9.1 for additional details regarding excluded systemic medications.&#xD;
&#xD;
               3. Have any known hypersensitivity or allergic reaction to any of the known&#xD;
                  ingredients in the anesthetic (proxymetacaine hydrochloride) or sodium&#xD;
                  fluorescein.&#xD;
&#xD;
               4. Have a history of cardiac disease or hyperthyroidism.&#xD;
&#xD;
               5. Have had any previous ocular or intraocular surgery (e.g., radial keratotomy,&#xD;
                  PRK, LASIK, cataract etc.)&#xD;
&#xD;
               6. Have participated in any ophthalmic clinical trial within 14 days prior to study&#xD;
                  enrolment.&#xD;
&#xD;
               7. Be an employee or immediate family member of an employee of clinical site (e.g.,&#xD;
                  Investigator, Coordinator, Technician).&#xD;
&#xD;
               8. Have a history of amblyopia or strabismus.&#xD;
&#xD;
               9. Have a history of contact lens wear. A trial period (up to one week) in the past&#xD;
                  is allowed.&#xD;
&#xD;
              10. Wear eye makeup on the days of the study visits.&#xD;
&#xD;
              11. Have clinically significant (grade 3 or higher on the Efron grading scale) slit&#xD;
                  lamp findings (e.g., corneal edema or neovascularization, conjunctival or limbal&#xD;
                  redness) or any other abnormality which would normally contraindicate&#xD;
                  participation in the study.&#xD;
&#xD;
              12. Have any ocular infection.&#xD;
&#xD;
              13. Have central lower eyelid Meibomian gland atrophy that exceeds 25%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Vision Care, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Vision Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Blackie, OD, PhD BCMAS</last_name>
    <phone>1-800-843-2020</phone>
    <email>cblackie@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

